Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Danaher (DHR) insider trading

Insider activity, historical context and SEC filings · data through Nov 20, 2026

Health CareDiagnostics & ResearchDHR

Closing price · Nov 19, 2026 $227.22 -0.6% on the day · +2.9% over 12 months 52-week range $161.29 – $240.61
Get DHR alerts
Open-market purchases0 insidersno buys · last 12 months
Insiders selling6last 12 months
Reported sales$36.0M0 of 26 recent sales pre-planned (10b5-1)
In 15 seconds

No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.

Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.
  • Next earnings expected around Jan 20, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Latest open-market trade

Sale Matthew McGrew, President sold 17,385 shares at $235.69 ($4.1M).

Trade date
Nov 9, 2026
Disclosed to the SEC
Nov 10, 2026
Type
Sale (code S)

Read the original SEC filing ↗All DHR insider trades ↓

Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.

DHR insider transactions (Form 4)

Open-market purchases and sales. 83 grants, option exercises and tax withholdings are not shown.

Filed Insider Type Shares Price Value Since Score
Nov 10SEC Matthew McGrewPresident Sell 17,38512,674 held (−58%) $235.69 $4.1M -3.6% —
Nov 10SEC Gregory M. MilosevichPresident Sell 2,10022,367 held (−9%) $230.62 $484K -1.5% —
Oct 29SEC Matthew McGrewPresident Sell 15,60312,674 held (−55%) $236.09 $3.7M -3.8% —
Oct 29SEC Matthew McGrewPresident Sell 14,15112,674 held (−53%) $235.35 $3.3M -3.5% —
Oct 29SEC Christopher BoudaVp, Chief Accounting Officer Sell 4,3459,107 held (−32%) $234.54 $1.0M -3.1% —
Oct 29SEC Christopher BoudaVp, Chief Accounting Officer Sell 3,2539,107 held (−26%) $234.58 $763K -3.1% —
Aug 24SEC Rainer BlairCEO, President Sell 39,1937,755 held (−83%) $218.73 $8.6M +3.9% —
Aug 24SEC Rainer BlairCEO, President Sell 11,30746,948 held (−19%) $217.77 $2.5M +4.3% —
Aug 24SEC Rainer BlairCEO, President Sell 7,755 $219.35 $1.7M +3.6% —
May 4SEC Alan G. SpoonDirector Sell 1,358124,094 held (−1%) $174.67 $237K +30.1% —
Feb 20SEC Gregory M. MilosevichPresident Sell 1,3205,099 held (−21%) $208.01 $275K +9.2% —
Nov 26SEC Mitchell P. RalesChair Sell 35,899854,726 held (−4%) $230.27 $8.3M -1.3% —
Nov 26SEC Mitchell P. RalesChair Sell 4,726850,000 held (−1%) $231.19 $1.1M -1.7% —
Nov 19SEC Teri ListDirector Sell 3,29820,762 held (−14%) $226.50 $747K +0.3% —
Nov 13SEC Mitchell P. RalesChair Sell 254,553709,820 held (−26%) $218.27 $55.6M +4.1% —
Nov 13SEC Mitchell P. RalesChair Sell 133,233576,587 held (−19%) $219.43 $29.2M +3.5% —
Nov 13SEC Mitchell P. RalesChair Sell 25,855964,373 held (−3%) $217.64 $5.6M +4.4% —
Nov 13SEC Mitchell P. RalesChair Sell 23,359553,228 held (−4%) $220.15 $5.1M +3.2% —
Nov 13SEC Matthew McGrewCFO Sell 16,17220,062 held (−45%) $214.62 $3.5M +5.9% —
Nov 13SEC Brian W. EllisPresident Sell 14,66714,553 held (−50%) $219.23 $3.2M +3.6% —
Nov 13SEC Brian W. EllisPresident Sell 7,10914,553 held (−33%) $219.21 $1.6M +3.7% —
Nov 12SEC Georgeann CoucharaSvp, Human Resources Sell 4,1763,623 held (−54%) $210.44 $879K +8.0% —
Nov 12SEC Georgeann CoucharaSvp, Human Resources Sell 9982,625 held (−28%) $210.31 $210K +8.0% —
Nov 4SEC Mitchell P. RalesChair Sell 308,4231,281,805 held (−19%) $215.67 $66.5M +5.4% —
Nov 4SEC Mitchell P. RalesChair Sell 223,4491,058,356 held (−17%) $216.26 $48.3M +5.1% —
Nov 4SEC Mitchell P. RalesChair Sell 68,128990,228 held (−6%) $217.17 $14.8M +4.6% —
Historical context

Similar past setups: not applicable. DHR has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →

Play with DHR in the Research Lab

DHR has no open-market insider buys in the last 12 months. Try the tools with any setup.

All tools →

Quick backtest: did buys like this beat the market?

Insiders buying
CEO or CFO
Dollar size
Stock before

Tap a setting to see how 6,290 past insider buys did.

Open the full Backtester →

Share price and insider trades

DHR closeInsider buyInsider sale
150175200225250DecJan 2026FebMarAprMayJunJulAugSepOctNovEEarnings release filed 2026-01-12EEarnings release filed 2026-01-28EEarnings release filed 2026-04-21EEarnings release filed 2026-07-21EEarnings release filed 2026-10-21Sold $237,207 on 2026-05-01 · Alan G. SpoonSold $274,575 on 2026-02-19 · Gregory M. MilosevichSold $4,581,754 on 2026-11-09 · Gregory M. Milosevich, Matthew McGrewSold $8,796,401 on 2026-10-28 · Christopher Bouda, Matthew McGrewSold $9,359,067 on 2025-11-25 · Mitchell P. RalesSold $12,736,095 on 2026-08-21 · Rainer Blair
Bought, 12 months$0
Sold, 12 months$36.0M
Insiders buying0
Insiders selling6

Danaher insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 6 sold $36.0M of DHR stock on the open market; P/E 38.2 vs. a sector median of 25.0.

By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this

DHR insider buying and selling by quarter

Open-market purchases (green, above the line) and sales (red, below), by trade date.

Q4 2025: $245M sold (15 trades)Q4 2025Q1 2026: $275K sold (1 trades)Q1 2026Q2 2026: $237K sold (1 trades)Q2 2026Q3 2026: $12.7M sold (3 trades)Q3 2026Q4 2026: $13.4M sold (6 trades)Q4 2026
QuarterBoughtPurchasesSoldSales
Q4 2026—0$13.4M6
Q3 2026—0$12.7M3
Q2 2026—0$237K1
Q1 2026—0$275K1
Q4 2025—0$245M15

Valuation, profit and volume

P/E (trailing)38.2Sector median 25.0
Market value$162.16BDiagnostics & Research
Profit margin16.9%Revenue growth +8.3%
Volume vs. 50-day0.7×Last 5 sessions

Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.

Summary

Over the past 12 months, 0 Danaher Corporation insiders reported open-market purchases totaling $0, while 6 insiders reported sales totaling $36.0M. 0 of 26 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.

DHR earnings: how the stock reacted

Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.

Does it matter? →
Release15 days beforeInsiders, 30 days beforeReaction (2 days)Next 30 days
Oct 21, 2026 +1.4% None +2.5%S&P -0.7% pending
Jul 21, 2026 +1.6% None -10.9%S&P +0.7% +22.2%
Apr 21, 2026 +2.3% None -5.9%S&P +0.4% -6.5%
Jan 28, 2026 -1.4% None -6.8%S&P -0.2% -4.1%
Jan 12, 2026 +3.1% None -1.2%S&P -0.0% -8.8%
Oct 21, 2025 -3.1% None +4.7%S&P -0.5% +4.3%
Jul 22, 2025 -7.4% None +5.2%S&P +0.9% +7.0%
Apr 22, 2025 +1.8% None +6.1%S&P +4.2% -6.0%

Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.

DHR short selling

Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.

20%40%60%2026-08-26: 45% of volume sold short2026-08-27: 37% of volume sold short2026-08-28: 50% of volume sold short2026-08-31: 37% of volume sold short2026-09-01: 38% of volume sold short2026-09-02: 29% of volume sold short2026-09-03: 51% of volume sold short2026-09-04: 26% of volume sold short2026-09-08: 40% of volume sold short2026-09-09: 46% of volume sold short2026-09-10: 51% of volume sold short2026-09-11: 28% of volume sold short2026-09-14: 40% of volume sold short2026-09-15: 26% of volume sold short2026-09-16: 45% of volume sold short2026-09-17: 46% of volume sold short2026-09-18: 37% of volume sold short2026-09-21: 51% of volume sold short2026-09-22: 45% of volume sold short2026-09-23: 54% of volume sold short2026-09-24: 21% of volume sold short2026-09-25: 32% of volume sold short2026-09-28: 53% of volume sold short2026-09-29: 56% of volume sold short2026-09-30: 28% of volume sold short2026-10-01: 44% of volume sold short2026-10-02: 50% of volume sold short2026-10-05: 35% of volume sold short2026-10-06: 52% of volume sold short2026-10-07: 48% of volume sold short2026-10-08: 40% of volume sold short2026-10-09: 37% of volume sold short2026-10-12: 39% of volume sold short2026-10-13: 48% of volume sold short2026-10-14: 31% of volume sold short2026-10-15: 30% of volume sold short2026-10-16: 51% of volume sold short2026-10-19: 52% of volume sold short2026-10-20: 38% of volume sold short2026-10-21: 38% of volume sold short2026-10-22: 36% of volume sold short2026-10-23: 45% of volume sold short2026-10-26: 53% of volume sold short2026-10-27: 46% of volume sold short2026-10-28: 51% of volume sold short2026-10-29: 45% of volume sold short2026-10-30: 39% of volume sold short2026-11-02: 39% of volume sold short2026-11-03: 36% of volume sold short2026-11-04: 51% of volume sold short2026-11-05: 37% of volume sold short2026-11-06: 38% of volume sold short2026-11-09: 33% of volume sold short2026-11-10: 55% of volume sold short2026-11-11: 44% of volume sold short2026-11-12: 39% of volume sold short2026-11-13: 37% of volume sold short2026-11-16: 32% of volume sold short2026-11-17: 22% of volume sold short2026-11-18: 36% of volume sold shortAug 26Sep 10Sep 24Oct 8Oct 22Nov 5
Latest (Nov 18): 36%20-day average: 40%Prior 2 months: 40%

This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →

Members of Congress who traded DHR

From STOCK Act disclosures. Reported up to 45 days after the trade, in dollar ranges.

All Congress trades →
MemberTradeTradedReportedSince trade
Alan ArmstrongSenate Bought $1,001 - $15,000 Mar 27, 2026Jul 21, 2026 +25.7%

Insiders at Danaher Corporation

InsiderBoughtSoldLast filingPast buys beat S&PScore
Mitchell P. RalesChair — $235M Oct 14, 2026 — —
Matthew McGrewPresident — $14.6M Nov 10, 2026 — —
Rainer BlairCEO, President — $12.7M Aug 24, 2026 — —
Brian W. EllisPresident — $4.8M Feb 6, 2026 — —
Christopher BoudaVp, Chief Accounting Officer — $1.8M Oct 29, 2026 — —
Georgeann CoucharaSvp, Human Resources — $1.1M May 19, 2026 — —
Gregory M. MilosevichPresident — $759K Nov 17, 2026 — —
Teri ListDirector — $747K May 19, 2026 — —
Alan G. SpoonDirector — $237K May 19, 2026 — —
Jonathan LeikenGeneral Counsel — — Nov 17, 2026 — —
Matthew E. GuginoCFO — — Nov 17, 2026 — —
Montgomery Julie A. SawyerCEO, President — — Nov 17, 2026 — —
Shashanka MuppaneniSvp, Chief Strategy Officer — — Nov 17, 2026 — —
Heathre T. MolerSvp, Chief Hr Officer — — Nov 17, 2026 — —
Daniel L. ComasDirector — — Nov 17, 2026 — —
Robert HershbergDirector — — Nov 17, 2026 — —
Steven M. RalesChair — — Oct 14, 2026 — —
Jose-Carlos Gutierrez-RamosSvp, Chief Science Officer — — Aug 6, 2026 — —
Christopher Paul RileyPresident — — Aug 6, 2026 — —
Elias A. ZerhouniDirector — — Jul 16, 2026 — —
Linda FillerDirector — — Jul 16, 2026 — —
Charles W. LamannaDirector — — May 19, 2026 — —
Feroz DewanDirector — — May 19, 2026 — —
A. Shane SandersDirector — — May 19, 2026 — —
Raymond C. StevensDirector — — May 19, 2026 — —
R. Bradley GraySvp Strategic Development — — Mar 3, 2026 — —

Board links: companies that share insiders with DHR

Directors and executives who filed Form 4s for DHR and another company in the last 12 months.

See the map →
  • VLTOVeralto Linda Filler Director here · Director at VLTO · latest filing Jul 17, 2026Daniel L. Comas Director here · Director at VLTO · latest filing Nov 17, 2026
  • ADPTAdaptive Biotechnologies Robert Hershberg Director here · Director at ADPT · latest filing Nov 17, 2026
  • CVLTCommvault Systems A. Shane Sanders Director here · Director at CVLT · latest filing Aug 10, 2026
  • ETREntergy Brian W. Ellis President here · Director at ETR · latest filing Sep 2, 2026
  • FTVFortive Daniel L. Comas Director here · Director at FTV · latest filing Nov 17, 2026
  • LULULululemon Athletica Teri List Director here · Director at LULU · latest filing Jun 29, 2026
  • MSFTMicrosoft Teri List Director here · Director at MSFT · latest filing Sep 8, 2026
  • RXRXRecursion Pharmaceuticals Robert Hershberg Director here · Director at RXRX · latest filing Nov 17, 2026
  • VVisa Teri List Director here · Director at V · latest filing May 19, 2026

Insider activity at other Health Care companies

Same sector, ranked by insider buying in the last 90 days.

  • KODKodiak Sciences Inc.$181M bought
  • BBTXBambusa Therapeutics, Inc.$52.6M bought
  • WWBWINDWARD BIO GROUP AG$49.8M bought
  • ADRXADARx Pharmaceuticals, Inc.$43.4M bought
  • PEPGPepGen Inc.$43.1M bought
  • LYCALycia Therapeutics, Inc.$38.5M bought

DHR stock: common questions

Are Danaher Corporation insiders buying DHR stock?

No. No Danaher Corporation insider reported an open-market purchase of DHR in the past 12 months.

Are Danaher Corporation insiders selling DHR stock?

6 insiders reported sales worth $36.0M over the same period.

Where does this data come from?

Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.

What is DHR's P/E ratio?

DHR trades at about 38.2 times trailing earnings, compared with a median of 25.0 for the Health Care sector.

What is DHR's 52-week range?

Over the past year DHR has traded between $161.29 and $240.61. It last closed at $227.22 on Nov 19, 2026.